January 4, 2018 / 1:09 PM / Updated 7 minutes ago BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab Reuters Staff 
Jan 4 (Reuters) - Exelixis Inc: 
* EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB 
* EXELIXIS INC - AMENDMENT ADDS FOUR NEW EXPANSION COHORTS TO PHASE 1B TRIAL, WHICH WILL NOW INCLUDE PATIENTS WITH NSCLC AND CRPC Source text for Eikon: Further company coverage: